businessbriefs
10:59in productionCh. 1 · Not a startup, but a consolidation/ 10:59 · ceiling 15 min
Companies · Strategy

Astellas Pharma

2005

A keiretsu-backed Japanese pharma merger that bought its way into oncology — but couldn’t fix its own dosing labels.

Astellas Pharma is a Japanese multinational pharmaceutical company formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. It operates globally with R&D centers in Japan, the US, and the Netherlands, and has pursued an aggressive acquisition strategy since inception — including OSI Pharmaceuticals, Ocata Therapeutics, Audentes Therapeutics, and Iveric Bio — while also facing regulatory scrutiny over marketing practices and product safety issues.

CompaniesStrategyMedicineGlobalisationSupply chainsMedicine across the network →
Chapters & takeaways4
  1. 1:10
    Not a startup, but a consolidation

    Astellas was not founded — it was assembled: two century-old Japanese firms merged on 1 April 2005.

  2. 3:13
    R&D centres were acquired, not built

    Its global R&D footprint predates the merger: Fujisawa built in Deerfield after 1990; Yamanouchi built in Leiderdorp after 1991.

  3. 4:42
    Safety failures exposed systemic execution gaps

    In 2009, Prograf and Advagraf caused patient harm in Europe due to preventable packaging and labeling failures.

  4. 6:23
    $4 billion for oncology access

    Astellas paid $4.0 billion for OSI Pharmaceuticals in 2010 — its first major post-merger acquisition to enter oncology.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • business/companies
  • business/strategy
  • business/deals-and-ipos
What does not
  • business/founders
  • business/startups-and-venture
  • business/ideas
Study it if
  • investors
  • regulatory analysts
  • healthcare strategists
Skip it if
  • consumers
  • patients
  • general public
The written brief1 min read

What the company or idea is

Astellas Pharma is a Japanese multinational pharmaceutical company formed on 1 April 2005 from the merger of Yamanouchi and Fujisawa.

How it actually makes money

Astellas makes money by selling prescription drugs — primarily immunosuppressants like Prograf and Advagraf, oncology agents, and urology treatments — to hospitals, pharmacies, and insurers globally.

What works

It inherited and expanded pre-existing overseas R&D centres: Fujisawa’s US hub in Deerfield (established after Lyphomed’s 1990 acquisition) and Yamanouchi’s Netherlands hub in Leiderdorp (established after Royal Gist Brocades’ 1991 acquisition).

What does not

Its post-merger safety controls failed in Europe: Prograf and Advagraf caused serious adverse reactions in 2009 due to packaging and labeling deficits.

What to take from it

The merger created a vertically integrated global player with legacy R&D infrastructure — but its aggressive acquisition strategy (e.g., OSI Pharmaceuticals for $4.0 billion in 2010) has not eliminated product safety or regulatory execution gaps.

Is it worth your time

Yes, if you are studying how keiretsu-aligned Japanese pharma firms consolidate R&D capability through acquisition while managing regulatory risk across markets.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

AstraZeneca

1913 · 10:30

AstraZeneca is not a British company — it is a 1999 merger with no disclosed financials, no stated cost model, and no evidence of how it actually delivers value beyond its own description.

Play nextBack to Companies
10:30